

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

宜明昂科生物醫藥技術（上海）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1541)

VOLUNTARY ANNOUNCEMENT APPROVAL BY NMPA FOR THE PHASE III CLINICAL TRIAL PROTOCOL OF IMM01 (TIMDARPACEPT)

This announcement is made by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders and potential investors of the Company about the latest business development of the Group.

The board (the “**Board**”) of directors (“**Directors**”, and each a “**Director**”) of the Company is pleased to announce that the Group has received approval from the National Medical Products Administration of the People's Republic of China (“**NMPA**”) for the protocol of the Phase III clinical trial of IMM01 (Timdarpcept) in combination with tislelizumab, targeting relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) patients who relapsed or progressed after the treatment of programmed cell death protein 1 (PD-1) inhibitors in April 2024.

ABOUT IMM01 (TIMDARPACEPT)

IMM01 (Timdarpcept), the Group's core product, is an innovative molecule targeting cluster of differentiation 47 (CD47). It is the first SIRP α -Fc fusion protein to enter into clinical stage in China. IMM01 (Timdarpcept) designed with immunoglobulin G1 (IgG1) Fc can fully activate macrophages via a dual mechanism — simultaneously blocking the “don't eat me” signal by disrupting CD47/SIRP α interaction and delivering the “eat me” signal through the engagement of activating Fc-gamma (Fc γ) receptors on macrophages. Furthermore, the CD47-binding domain of IMM01 (Timdarpcept) was specifically engineered to avoid human red blood cell (RBC) binding. With the differentiated molecule design, IMM01 (Timdarpcept) has achieved a favorable safety profile and demonstrated its ability to activate macrophages.

The Group owns the global intellectual property rights and commercial rights of IMM01 (Timdarpaccept). As of the date of this announcement, in relation to IMM01 (Timdarpaccept), the Group owned one patent family, which includes issued patents in China, the United States, Japan and the European Union.

For further information with respect to the development of IMM01 (Timdarpaccept), please refer to the Company's announcement of annual results for the year ended December 31, 2023 dated March 25, 2024.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to develop, or ultimately market, IMM01 (Timdarpaccept), successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the Shares of the Company.

By order of the Board
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
宜明昂科生物醫藥技術(上海)股份有限公司
Tian Wenzhi
Chairman and Executive Director

Hong Kong, April 17, 2024

As at the date of this announcement, the Board of Directors comprises (i) Dr. Tian Wenzhi and Mr. Li Song as executive Directors; (ii) Dr. Xu Cong, Mr. Yu Zhihua and Mr. Yu Xiaoyong as non-executive Directors; and (iii) Dr. Zhenping Zhu, Dr. Kendall Arthur Smith and Mr. Yeung Chi Tat as independent non-executive Directors.